Literature DB >> 8215294

Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116.

G E Kenny1, F D Cartwright.   

Abstract

The susceptibilities of human mycoplasmas to OPC 17116 (Otsuka America Pharmaceutical, Inc., Rockville, Md.) and temafloxacin (Abbott Laboratories, Chicago, Ill.) were determined by the agar dilution method and were compared with those to sparfloxacin and ofloxacin. The MICs of OPC 17116 for 90% of Mycoplasma pneumoniae (0.25 microgram/ml) and Mycoplasma hominis (0.125 micrograms/ml) isolates tested were closely similar to those of sparfloxacin and were four- to eightfold greater than those of ofloxacin. Temafloxacin was two- to fourfold more active than ofloxacin. Ureaplasma urealyticum was less susceptible; the MICs of OPC 17116 and temafloxacin for 90% of isolates tested were 2 and 4.0 micrograms/ml, respectively.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8215294      PMCID: PMC188054          DOI: 10.1128/AAC.37.8.1726

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

Review 1.  The crisis in antibiotic resistance.

Authors:  H C Neu
Journal:  Science       Date:  1992-08-21       Impact factor: 47.728

2.  Activity of temafloxacin against respiratory pathogens.

Authors:  R N Swanson; D J Hardy; D T Chu; N L Shipkowitz; J J Clement
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

3.  Susceptibility of Mycoplasma pneumoniae to several new quinolones, tetracycline, and erythromycin.

Authors:  G E Kenny; F D Cartwright
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

4.  In vitro activity of sparfloxacin (CI-978, AT-4140, and PD 131501). A quinolone with high activity against gram-positive bacteria.

Authors:  M A Cohen; M D Huband; G B Mailloux; S L Yoder; G E Roland; C L Heifetz
Journal:  Diagn Microbiol Infect Dis       Date:  1991 Sep-Oct       Impact factor: 2.803

5.  Susceptibilities of genital mycoplasmas to the newer quinolones as determined by the agar dilution method.

Authors:  G E Kenny; T M Hooton; M C Roberts; F D Cartwright; J Hoyt
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

6.  WIN 57273, a new fluoroquinolone with enhanced in vitro activity versus gram-positive pathogens.

Authors:  G W Kaatz; S M Seo
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

7.  Dissemination of the tetM tetracycline resistance determinant to Ureaplasma urealyticum.

Authors:  M C Roberts; G E Kenny
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

8.  Susceptibilities of Mycoplasma hominis and Ureaplasma urealyticum to two new quinolones, sparfloxacin and WIN 57273.

Authors:  G E Kenny; F D Cartwright
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

9.  Tetracycline-resistant Mycoplasma hominis strains contain streptococcal tetM sequences.

Authors:  M C Roberts; L A Koutsky; K K Holmes; D J LeBlanc; G E Kenny
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

10.  In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones.

Authors:  K B Waites; G H Cassell; K C Canupp; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

View more
  12 in total

1.  In vitro activity of a new quinoline derivative, ER-2, against clinical isolates of Mycoplasma pneumoniae and Mycoplasma hominis.

Authors:  Shilpakala Sainath Rao; Raghavachari Raghunathan; Ramesh Ekambaram; Malathi Raghunathan
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191

2.  Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219).

Authors:  G E Kenny; F D Cartwright
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

3.  In vitro activity of BAY 12-8039, a new fluoroquinolone against mycoplasmas.

Authors:  C M Bébéar; H Renaudin; A Boudjadja; C Bébéar
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

4.  Sparfloxacin selects gyrase mutations in first-step Mycoplasma hominis mutants, whereas ofloxacin selects topoisomerase IV mutations.

Authors:  G E Kenny; P A Young; F D Cartwright; K E Sjöström; W M Huang
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

5.  In vitro susceptibilities of Mycoplasma hominis to six fluoroquinolones as determined by E test.

Authors:  K B Waites; K C Canupp; G E Kenny
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

6.  In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae.

Authors:  P M Roblin; G Montalban; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

7.  Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily.

Authors:  S Chodosh; S Lakshminarayan; H Swarz; S Breisch
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

8.  Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to new glycylcyclines in comparison with those to older tetracyclines.

Authors:  G E Kenny; F D Cartwright
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

9.  In vitro antimycoplasmal activities of rufloxacin and its metabolite MF 922.

Authors:  P M Furneri; G Bisignano; G Cerniglia; G Nicoletti; M Cesana; G Tempera
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

10.  Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.

Authors:  C M Salvatore; C Techasaensiri; C Tagliabue; K Katz; N Leos; A M Gomez; G H McCracken; R D Hardy
Journal:  Antimicrob Agents Chemother       Date:  2009-01-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.